Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ST PETER PORT, Guernsey and LONDON, July 6 /PRNewswire/ --

- GBP13.1 Million Funding to Drive Novel Antibiotics Platform Addressing Areas of Major Unmet Need, Including Hospital Acquired Infections C. Difficile and MRSA

Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP ("CP2"), today announces its investment in a majority shareholding in Novacta Biosystems Limited ("Novacta"), which is developing a portfolio of antibiotics. The total being raised is GBP13.1m ($21.6m), payable against pre-agreed milestones. As part of this investment certain existing investors are re-investing.

Novacta is a UK-based company developing novel, naturally-derived products known as 'lantibiotics' as potential drugs. Lantibiotics have potent anti-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed through its proprietary technology platform. The most advanced programme will enter the clinic next year to treat infections caused by Clostridium difficile ("C. difficile"). The Wellcome Trust has provided in the order of GBP4m of translational funding to Novacta since 2004 for the development of the platform technology and more recently the C. difficile programme.

New anti-infective drugs are needed to target C. difficile without depleting other beneficial bacteria in the gut and preclinical data show that Novacta's lead lantibiotics selectively kill C. difficile with less disturbance of normal gut bacteria than seen with existing drugs. C. difficile infections (CDIs) are a serious problem: the number of cases grew by 22 percent in the UK last year, accounting for twice as many deaths as MRSA.

Novacta's pipeline also includes programmes targeting other areas of unmet medical need in bacterial infection. These include novel prom
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... (PRWEB) December 12, 2014 Trend lines ... in overall global economic growth, Eugene Arthurs, CEO of ... , said in a featured talk at OPTIC (Optics ... at the National Chung Hsing University in Taichung. , ... integrated into future energy supplies and soon to hit ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... 12, 2014  Vaccinex Inc., a clinical-stage ... development of therapeutic monoclonal antibodies to treat ... of a manuscript entitled "SEMA4D compromises blood–brain ... neurodegenerative disease" in the January 2015 issue ... publication highlights an important role for antibodies ...
(Date:12/12/2014)... (PRWEB) December 11, 2014 Graphite Metallizing ... materials for pumps and process equipment, has appointed Kirk ... States and Ontario, Canada. Staller holds a B.S. degree ... in the industrial market place, much of it with ... out of his Michigan office. , “We are ...
Breaking Biology Technology:Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Kirk Staller Joins Graphite Metallizing Corporation 2
... Total Site Solutions,(TSS), a Fortress International Group Company ... the planning, design and development of,mission-critical facilities today ... industry has awarded them the construction,management phase of ... performed technology consulting services to analyze,short term and ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
... leader in,the rapidly evolving field of cancer molecular diagnostics, ... Lindenbergh as Chairman of its,Supervisory Board. Hessel Lindenbergh ... ING,Group N.V.. Currently, Mr. Lindenbergh is chairman of the ... the Royal Numico, Petroplus,International and Gamma Holding. Mr. Lindenbergh ...
Cached Biology Technology:Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 3Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board 2
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... a study has compared water quality trends in forested streams ... or land cover changes. The study, which draws on ... states and Puerto Rico, underscores the value of long-term data ... in streams and rivers. It is published in the current ...
... sick with colon cancer, received a blood transfusion. Then, unexpectedly, ... on her case, the French medical journal Revue D,Hmatologie identified ... it turns out, Mrs. Vel had developed a potent antibody ... of most people in the worldbut not found on her ...
... Philanthropist, businessman and community leader John Moores has given ... fund the development of a new field test for ... tens of millions of people in Africa, Latin America ... John,s generosity and foresight," said Michael A. Marletta, president ...
Cached Biology News:Study explores long-term water quality trends in near-pristine streams 2Baffling blood problem explained 2Baffling blood problem explained 3John Moores gives $2 million to Scripps Research to develop river blindness field test 2
... monoclonal antibody irreversibly crosslinked to protein G-agarose ... PDH complex from heart mitochondria. Also included ... for control immunocapture. ,The pyruvate dehydrogenase complex ... from small amounts of tissue. This facilitates ...
... innovative reagent for highly efficient transfer of ... cells. Unlike DNA transfection, with PULSin Protein ... timing of exogenous proteins in cells can ... be studied. Real time function blocking ...
... ST-195 allows real-time observations of cell cultures ... has 64 different strain parameters in addition ... thin silicon strain chamber used by the ... fluorescence microscopy. ST-195 can be used with ...
... demands on cell and tissue culture assumes ... Therefore, both cell concentration and percentage of ... precisely. The new Vi-CELLTM Cell Viability Analyzer ... to perform the trypan blue dye exclusion ...
Biology Products: